Publications by authors named "Robert R Conley"

Claim this Profile
P
Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment.
David W Dodick, Peter J Goadsby, Christian Lucas, Rigmor Jensen, Jennifer N Bardos, Robert R Conley

Cephalalgia· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trial of Galcanezumab in Prevention of Episodic Cluster Headache.
Peter J Goadsby, David W Dodick, Massimo Leone, Jennifer N Bardos, Tina M Oakes, Robert R Conley

N Engl J Med· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.
Virginia L Stauffer, David W Dodick, Qi Zhang, Jeffrey N Carter, Jessica Ailani, Robert R Conley

JAMA Neurol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protecting confidentiality in human research.
Bryon Adinoff, Robert R Conley, Stephan F Taylor, Linda L Chezem

Am J Psychiatry· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study.
Kimberly R Warren, Robert W Buchanan, Stephanie Feldman, Robert R Conley, Jared Linthicum

J Clin Psychopharmacol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dopamine pathology in schizophrenia: analysis of total and phosphorylated tyrosine hydroxylase in the substantia nigra.
Emma Perez-Costas, Miguel Melendez-Ferro, Matthew W Rice, Robert R Conley, Rosalinda C Roberts

Front Psychiatry· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States.
Haya Ascher-Svanum, Nicolas M Furiak, Anthony H Lawson, Timothy M Klein, Lee J Smolen, Robert R Conley

J Med Econ· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis.
Wenyu Ye, Haya Ascher-Svanum, Yuka Tanji, Jennifer A Flynn, Michihiro Takahashi, Robert R Conley

Neuropsychiatr Dis Treat· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
John P Houston, Jared Kohler, Jeffrey R Bishop, Vicki L Ellingrod, Katherine M Ostbye, Robert R Conley

J Clin Psychiatry· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone.
Bonnie A Fijal, Virginia L Stauffer, Bruce J Kinon, Robert R Conley, Vicki Poole Hoffmann

J Clin Psychiatry· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms.
Virginia L Stauffer, Guochen Song, Bruce J Kinon, Haya Ascher-Svanum, Lei Chen, Robert R Conley

Schizophr Res· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.
Douglas L Boggs, Deanna L Kelly, Robert P McMahon, James M Gold, David A Gorelick, Robert R Conley

Schizophr Res· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Striatal mitochondria in subjects with chronic undifferentiated vs. chronic paranoid schizophrenia.
Shahza M Somerville, Robert R Conley, Rosalinda C Roberts

Synapse· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Researcher experiences with IRBs: a survey of members of the American College of Neuropsychopharmacology.
Katherine L Wisner, Robert R Conley, Stephan F Taylor, Thomas Kosten, Mark Hyman Rapaport

IRB· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia.
Xiaomei Peng, Haya Ascher-Svanum, Douglas Faries, Robert R Conley, Kory J Schuh

Clinicoecon Outcomes Res· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitochondria in the striatum of subjects with schizophrenia: relationship to treatment response.
Shahza M Somerville, Adrienne C Lahti, Robert R Conley, Rosalinda C Roberts

Synapse· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitochondria in the striatum of subjects with schizophrenia.
Shahza M Somerville, Robert R Conley, Rosalinda C Roberts

World J Biol Psychiatry· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.
Deanna L Kelly, David A Gorelick, Robert R Conley, Douglas L Boggs, Jared Linthicum

J Clin Psychopharmacol· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia.
Stephen J Ruberg, Lei Chen, Virginia Stauffer, Haya Ascher-Svanum, Sara Kollack-Walker, Robert R Conley

BMC Psychiatry· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled clinical trials.
Vicki P Hoffmann, Michael Case, Virginia L Stauffer, Jennie G Jacobson, Robert R Conley

J Clin Psychopharmacol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine.
Elaine Weiner, Robert R Conley, M Patricia Ball, Stephanie Feldman, James M Gold

Neuropsychopharmacology· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia.
Deanna L Kelly, Stephanie Feldman, Douglas L Boggs, Elizabeth Gale, Robert R Conley

Compr Psychiatry· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis